CytomX Therapeutics (CTMX) Issues Strategic Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
CytomX Therapeutics Provides Strategic Update
July 13, 2022 4:05 PM EDT- Company to focus internal efforts on wholly-owned next-generation conditionally activated therapeutics, including IFN alpha-2b cytokine and EpCAM-directed ADC, INDs planned for 2023 -
- Partnered clinical-stage programs continue to advance: Phase 2 programs, BMS-986249 (anti-CTLA-4) and CX-2029 (anti-CD71 ADC); and Phase 1 programs, CX-904 (EGFRxCD3 bispecific) and BMS-986288 (anti-CTLA-4) -
- Company restructuring to realign capital resources and extend cash runway to 2025 -
- Company to host conference call and webcast today at 6:00 pm ET / 3:00 pm PT -
SOUTH SAN FRANCISCO, Calif., July 13,... More
